BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account

The association between central lymph node metastasis (LNM) and risk factors, including the presence of the BRAF mutation, BRAF(V600E), in patients with papillary thyroid cancer (PTC) requires further investigation. A potent risk factor that can indicate LNM in different histological subtypes of PTC...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Si-Yang, Zeng, Rui-Chao, Jin, Lang-Ping, Yang, Fan, Zhang, Xiang-Jian, Yao, Zhi-Han, Zhang, Xiao-Hua, Wang, Ou-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604127/
https://www.ncbi.nlm.nih.gov/pubmed/28943919
http://dx.doi.org/10.3892/ol.2017.6694
_version_ 1783264814366195712
author Dong, Si-Yang
Zeng, Rui-Chao
Jin, Lang-Ping
Yang, Fan
Zhang, Xiang-Jian
Yao, Zhi-Han
Zhang, Xiao-Hua
Wang, Ou-Chen
author_facet Dong, Si-Yang
Zeng, Rui-Chao
Jin, Lang-Ping
Yang, Fan
Zhang, Xiang-Jian
Yao, Zhi-Han
Zhang, Xiao-Hua
Wang, Ou-Chen
author_sort Dong, Si-Yang
collection PubMed
description The association between central lymph node metastasis (LNM) and risk factors, including the presence of the BRAF mutation, BRAF(V600E), in patients with papillary thyroid cancer (PTC) requires further investigation. A potent risk factor that can indicate LNM in different histological subtypes of PTC and in different preoperative central lymph node statuses also requires further research. A total of 287 patients with PTC who accepted thyroidectomy were included in the present study. Clinicopathological data of these patients were reviewed to examine the risk factors for central LNM through univariate and multivariate analyses. Overall, BRAF(V600E) in patients with cN0 (subclinical nodal disease) and cN1 (other than cN0) PTC was associated with central LNM. However, multivariate analyses demonstrated that BRAF(V600E) was not an independent risk factor in patients with cN1 or cN0 PTC. For patients with classical variant PTC (CVPTC), BRAF(V600E) was independently associated with central LNM. However, on further analysis, the association was only significant in patients with cN0 CVPTC. For patients with follicular variant PTC (FVPTC) or aggressive variant PTC (AVPTC), the BRAF(V600E) mutation rate was not significantly different between patients with and without central LNM. In conclusion, BRAF(V600E) was an independent risk factor for central LNM overall in patients with PTC and in patients with CVPTC, particularly in patients with cN0 CVPTC. However, BRAF(V600E) was not an independent risk factor for patients with FVPTC and AVPTC. Therefore, BRAF(V600E) provides varied clinical significance in different histological subtypes and preoperative central lymph node status.
format Online
Article
Text
id pubmed-5604127
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-56041272017-09-22 BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account Dong, Si-Yang Zeng, Rui-Chao Jin, Lang-Ping Yang, Fan Zhang, Xiang-Jian Yao, Zhi-Han Zhang, Xiao-Hua Wang, Ou-Chen Oncol Lett Articles The association between central lymph node metastasis (LNM) and risk factors, including the presence of the BRAF mutation, BRAF(V600E), in patients with papillary thyroid cancer (PTC) requires further investigation. A potent risk factor that can indicate LNM in different histological subtypes of PTC and in different preoperative central lymph node statuses also requires further research. A total of 287 patients with PTC who accepted thyroidectomy were included in the present study. Clinicopathological data of these patients were reviewed to examine the risk factors for central LNM through univariate and multivariate analyses. Overall, BRAF(V600E) in patients with cN0 (subclinical nodal disease) and cN1 (other than cN0) PTC was associated with central LNM. However, multivariate analyses demonstrated that BRAF(V600E) was not an independent risk factor in patients with cN1 or cN0 PTC. For patients with classical variant PTC (CVPTC), BRAF(V600E) was independently associated with central LNM. However, on further analysis, the association was only significant in patients with cN0 CVPTC. For patients with follicular variant PTC (FVPTC) or aggressive variant PTC (AVPTC), the BRAF(V600E) mutation rate was not significantly different between patients with and without central LNM. In conclusion, BRAF(V600E) was an independent risk factor for central LNM overall in patients with PTC and in patients with CVPTC, particularly in patients with cN0 CVPTC. However, BRAF(V600E) was not an independent risk factor for patients with FVPTC and AVPTC. Therefore, BRAF(V600E) provides varied clinical significance in different histological subtypes and preoperative central lymph node status. D.A. Spandidos 2017-10 2017-08-01 /pmc/articles/PMC5604127/ /pubmed/28943919 http://dx.doi.org/10.3892/ol.2017.6694 Text en Copyright: © Dong et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Dong, Si-Yang
Zeng, Rui-Chao
Jin, Lang-Ping
Yang, Fan
Zhang, Xiang-Jian
Yao, Zhi-Han
Zhang, Xiao-Hua
Wang, Ou-Chen
BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account
title BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account
title_full BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account
title_fullStr BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account
title_full_unstemmed BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account
title_short BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account
title_sort braf(v600e) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: different histological subtypes and preoperative lymph node status should be taken into account
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604127/
https://www.ncbi.nlm.nih.gov/pubmed/28943919
http://dx.doi.org/10.3892/ol.2017.6694
work_keys_str_mv AT dongsiyang brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount
AT zengruichao brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount
AT jinlangping brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount
AT yangfan brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount
AT zhangxiangjian brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount
AT yaozhihan brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount
AT zhangxiaohua brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount
AT wangouchen brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount